For Highly Aggressive Acute Myeloid Leukemia (AML), CX-5461 May Be Effective
CX-5461, which that inhibits RNA polymerase 1, may improve survival for patients with highly aggressive acute myeloid leukemia.
Diagnosis & Disease Information
FDA Fast Tracks AG-221 to Treat AML
The FDA has granted Fast Track designation to AG-221, a first-in-classinhibitor, to treat AML.
Older Acute Myeloid Leukemia Patients May Benefit From Volasertib
Objective response rate more than doubled in older patients with acute myeloid leukemia receiving volasertib.
AML Regimen Produced Mixed Results in Older Patients
Older patients experienced benefits when treated with azacitidine, but the results were not statistically significant.
Epigenetic Therapy Active Against Some Hematologic Cancers
Patients with a variety of hematologic cancers benefited from treatment with OTX015, a member of a new class of investigational epigenetic therapies that block the activity of bromodomain and extraterminal (BET)-bromodomain proteins.
New Drug May Be Game Changer for AML
Clinical trials for a new experimental drug, CPX-351, to treat acute myeloid leukemia are very promising, according to researchers.
Experimental Drug Shows Promise for Treatment-resistant Leukemia
The experimental compound dubbed TTT-3002 has been identified as a potent means to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia, according to research.
Alvocidib Receives Orphan Drug Designation for AML
The FDA has granted Orphan Drug designation to alvocidib for the treatment of patients with acute myeloid leukemia.
Volasertib Designated Orphan Drug for AML
The FDA has granted Orphan Drug designation to volasertib (Boehringer Ingelheim) for acute myeloid leukemia (AML).
FDA Grants ERY-ASP Orphan Drug Designation for AML
The FDA has granted ERY-ASP (Erytech Pharma) Orphan Drug Designation for the treatment of acute myeloid leukemia (AML).
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...